SAN DIEGO (July 11, 2016) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that it received a “No Objection Letter” from the USDA’s Food Safety and Inspection Service (FSIS) granting approval for SDC-based PURE Control to be used as a spray or dip applied to poultry carcasses, parts and organs in pre-OLR (on-line reprocessing) and post chill processing of fresh poultry. PURE Control will be listed in FSIS’ Directive 7120.1, “Safe and Suitable Ingredients Used in the Production of Meat, Poultry and Egg Products” in the next scheduled revision.
Begins Immediate Commercialization for Pre-OLR and Post Chill Applications
The commercialization of PURE Control for these newly approved applications is underway and the Company is already in discussions with several major poultry processors to begin in-plant validation and optimization testing.
The approval for these new uses allows immediate access to multiple poultry processing application points outside of OLR and enables PURE to begin sales to poultry processors.
Hank R. Lambert, Chief Executive Officer, said that, “We are pleased to achieve another important milestone in our strategy to introduce our game changing SDC technology to poultry processors. With this ‘No Objection Letter’ and 7120.1 listing in hand, we are moving forward with several of the top poultry processors to evaluate using PURE Control in their plants. As with each first time user of PURE Control, that process will include in-plant validation and optimization analysis over the next few months.”
PURE continues its on-going plant trials to optimize the application of PURE Control in OLR to gain USDA approval for use in that stage of poultry processing and anticipates completion in the third calendar quarter this year.
A non-toxic intervention to dramatically reduce prevalent pathogens including Salmonella and Campylobacter, PURE Control can now be applied to poultry carcasses and parts during processing before the OLR stage and after the immersion chiller stage.
PURE Control maximizes microbial control and is highly effective against Salmonella, Listeria, E. coli, Campylobacter and many other pathogens. During extensive laboratory testing, and in simulated plant conditions, application of PURE Control to raw poultry carcasses during processing has demonstrated the potential to reduce Salmonella to below detection levels. The plant trials and testing that PURE is conducting are anticipated to confirm a meaningful reduction in pathogens in commercial application. This addresses the top priority of the USDA in its Salmonella Action Plan, to reduce the presence of Salmonella in poultry sold to consumers by 50% from current levels. Presently approximately 28% of raw poultry sold to consumers contains Salmonella.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2015, its Form 10-Q for the first quarter ended October 31, 2015 and its Form 10-Q for the second quarter ended January 31, 2016, and its Form 10-Q for the third quarter ended April 30, 2016. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Hank Lambert, CEO Terri MacInnis, VP of IR Tom Hemingway
PURE Bioscience, Inc. Bibicoff + MacInnis, Inc. Redwood Investment Group
619-596-8600 ext.103 818-379-8500 714-978-4425